{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:13:50Z","timestamp":1793330030900,"version":"4.5.0"},"publisher-location":"Cham","reference-count":78,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030573683","type":"print"},{"value":"9783030573690","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-57369-0_3","type":"book-chapter","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T09:26:59Z","timestamp":1608197219000},"page":"29-45","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review"],"prefix":"10.1007","author":[{"given":"Rafael G.","family":"dos Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime E. C.","family":"Hallak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Alexandre S.","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"3_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejim.2018.01.019","volume":"49","author":"R Abuhasira","year":"2018","unstructured":"Abuhasira R, Schleider LB, Mechoulam R et al (2018) Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med 49:44\u201350","journal-title":"Eur J Intern Med"},{"key":"3_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejim.2018.01.001","volume":"49","author":"R Abuhasira","year":"2018","unstructured":"Abuhasira R, Shbiro L, Landschaft Y (2018) Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America. Eur J Intern Med 49:2\u20136","journal-title":"Eur J Intern Med"},{"key":"3_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fpls.2016.00019","volume":"7","author":"CM Andre","year":"2016","unstructured":"Andre CM, Hausman JF, Guerriero G (2016) Cannabis sativa: the plant of the thousand and one molecules. Front Plant Sci 7:19","journal-title":"Front Plant Sci"},{"issue":"1","key":"3_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/can.2017.0047","volume":"3","author":"C Beale","year":"2018","unstructured":"Beale C, Broyd SJ, Chye Y et al (2018) Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users. Cannabis Cannabinoid Res 3(1):94\u2013107","journal-title":"Cannabis Cannabinoid Res"},{"issue":"3","key":"3_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.9740\/mhc.2018.05.110","volume":"8","author":"T Bellnier","year":"2018","unstructured":"Bellnier T, Brown GW, Ortega TR (2018) Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis. Ment Health Clin 8(3):110\u2013115","journal-title":"Ment Health Clin"},{"key":"3_CR6","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RH, Chagas MH et al (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36:1219\u20131226","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"3_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/157488611798280924","volume":"6","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RH, Zuardi AW et al (2011) Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 6(4):237\u2013249","journal-title":"Curr Drug Saf"},{"issue":"1","key":"3_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1001\/archgenpsychiatry.2011.161","volume":"69","author":"S Bhattacharyya","year":"2012","unstructured":"Bhattacharyya S, Crippa JA, Allen P et al (2012) Induction of psychosis by \u03949-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry 69(1):27\u201336","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"3_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/archgenpsychiatry.2009.17","volume":"66","author":"S Bhattacharyya","year":"2009","unstructured":"Bhattacharyya S, Fusar-Poli P, Borgwardt S et al (2009) Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 66(4):442\u2013451","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"3_CR10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/npp.2009.184","volume":"5","author":"S Bhattacharyya","year":"2010","unstructured":"Bhattacharyya S, Morrison PD, Fusar-Poli P et al (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 5(3):764\u2013774","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"3_CR11","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/epi.14555","volume":"59","author":"M Bialer","year":"2018","unstructured":"Bialer M, Johannessen SI, Koepp MJ et al (2018) Progress report on new antiepileptic drugs: a summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development. Epilepsia 59(10):1842\u20131866","journal-title":"Epilepsia"},{"issue":"4","key":"3_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000492757","volume":"24","author":"JG Bramness","year":"2018","unstructured":"Bramness JG, Dom G, Gual A et al (2018) A Survey on the Medical Use of Cannabis in Europe: a Position Paper. Eur Addict Res 24(4):201\u2013205","journal-title":"Eur Addict Res"},{"key":"3_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fphar.2017.00269","volume":"8","author":"AC Campos","year":"2017","unstructured":"Campos AC, Foga\u00e7a MV, Scarante FF et al (2017) Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders. Front Pharmacol 8:269","journal-title":"Front Pharmacol"},{"key":"3_CR14","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","volume":"28","author":"MH Chagas","year":"2014","unstructured":"Chagas MH, Zuardi AW, Tumas V et al (2014) Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial. J Psychopharmacol 28:1088\u20131098","journal-title":"J Psychopharmacol"},{"key":"3_CR15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/0091-3057(82)90418-X","volume":"16","author":"BK Colasanti","year":"1982","unstructured":"Colasanti BK, Lindamood C 3rd, Craig CR (1982) Effects of marijuana cannabinoids on seizure activity in cobalt-epileptic rats. Pharmacol Biochem Behav 16:573\u2013578","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"3_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s40429-017-0142-2","volume":"4","author":"M Colizzi","year":"2017","unstructured":"Colizzi M, Bhattacharyya S (2017) Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition. Curr Addict Rep 4(2):62\u201374","journal-title":"Curr Addict Rep"},{"key":"3_CR17","first-page":"26","volume":"201","author":"P Consroe","year":"1977","unstructured":"Consroe P, Wolkin A (1977) Cannabidiol \u2013 antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther 201:26\u201332","journal-title":"J Pharmacol Exp Ther"},{"key":"3_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3389\/fphar.2016.00359","volume":"7","author":"JA Crippa","year":"2016","unstructured":"Crippa JA, Crippa AC, Hallak JE et al (2016) \u03949-THC Intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol. Front Pharmacol 7:359","journal-title":"Front Pharmacol"},{"key":"3_CR19","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.3389\/fimmu.2018.02009","volume":"9","author":"JA Crippa","year":"2018","unstructured":"Crippa JA, Guimar\u00e3es FS, Campos AC et al (2018) Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): toward a new age. Front Immunol 9:2009","journal-title":"Front Immunol"},{"issue":"1","key":"3_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1089\/can.2017.0059","volume":"3","author":"B de Hoop","year":"2018","unstructured":"de Hoop B, Heerdink ER, Hazekamp A (2018) Medicinal cannabis on prescription in The Netherlands: statistics for 2003-2016. Cannabis Cannabinoid Res 3(1):54\u201355","journal-title":"Cannabis Cannabinoid Res"},{"issue":"3","key":"3_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","volume":"2","author":"M Di Forti","year":"2015","unstructured":"Di Forti M, Marconi A, Carra E et al (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2(3):233\u2013238","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"3_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jcpt.12235","volume":"40","author":"RG dos Santos","year":"2015","unstructured":"dos Santos RG, Hallak JE, Leite JP et al (2015) Phytocannabinoids and epilepsy. J Clin Pharm Ther 40(2):135\u2013143","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"3_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1177\/0269881115615104","volume":"30","author":"A Englund","year":"2016","unstructured":"Englund A, Atakan Z, Kralj A et al (2016) The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: a placebo-controlled, double-blind, crossover pilot trial. J Psychopharmacol 30(2):140\u2013151","journal-title":"J Psychopharmacol"},{"issue":"1","key":"3_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","volume":"66","author":"P Fusar-Poli","year":"2009","unstructured":"Fusar-Poli P, Crippa JA, Bhattacharyya S et al (2009) Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 66(1):95\u2013105","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"3_CR25","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.13852","volume":"58","author":"TE Gaston","year":"2017","unstructured":"Gaston TE, Bebin EM, Cutter GR et al (2017) Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia 58(9):1586\u20131592","journal-title":"Epilepsia"},{"key":"3_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.neuro.2015.08.007","volume":"50","author":"PH Gobira","year":"2015","unstructured":"Gobira PH, Vilela LR, Gon\u00e7alves BD et al (2015) Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: possible role of the mTOR pathway and reduction in glutamate release. Neurotoxicology 50:116\u2013121","journal-title":"Neurotoxicology"},{"issue":"7","key":"3_CR27","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.euroneuro.2018.04.004","volume":"28","author":"O Grimm","year":"2018","unstructured":"Grimm O, L\u00f6ffler M, Kamping S et al (2018) Probing the endocannabinoid system in healthy volunteers: cannabidiol alters fronto-striatal resting-state connectivity. Eur Neuropsychopharmacol 28(7):841\u2013849","journal-title":"Eur Neuropsychopharmacol"},{"key":"3_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3389\/fphar.2016.00355","volume":"7","author":"SA Gruber","year":"2016","unstructured":"Gruber SA, Sagar KA, Dahlgren MK et al (2016) Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function. Front Pharmacol 7:355","journal-title":"Front Pharmacol"},{"key":"3_CR29","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3389\/fphar.2017.00983","volume":"8","author":"SA Gruber","year":"2018","unstructured":"Gruber SA, Sagar KA, Dahlgren MK et al (2018) The Grass Might Be Greener: medical marijuana patients exhibit altered brain activity and improved executive function after 3 months of treatment. Front Pharmacol 8:983","journal-title":"Front Pharmacol"},{"issue":"7","key":"3_CR30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.braindev.2018.03.013","volume":"40","author":"M Hausman-Kedem","year":"2018","unstructured":"Hausman-Kedem M, Menascu S, Kramer U (2018) Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study. Brain and Development 40(7):544\u2013551","journal-title":"Brain and Development"},{"key":"3_CR31","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/bph.12321","volume":"170","author":"TD Hill","year":"2013","unstructured":"Hill TD, Cascio MG, Romano B et al (2013) Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol 170:679\u2013692","journal-title":"Br J Pharmacol"},{"key":"3_CR32","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1111\/j.1476-5381.2012.02207.x","volume":"167","author":"AJ Hill","year":"2012","unstructured":"Hill AJ, Mercier MS, Hill TD et al (2012) Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol 167:1629\u20131642","journal-title":"Br J Pharmacol"},{"key":"3_CR33","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1111\/j.1528-1167.2010.02523.x","volume":"51","author":"AJ Hill","year":"2010","unstructured":"Hill AJ, Weston SE, Jones NA et al (2010) Delta9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia 51:1522\u20131532","journal-title":"Epilepsia"},{"key":"3_CR34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10722-003-4452-y","volume":"52","author":"KW Hillig","year":"2005","unstructured":"Hillig KW (2005) Genetic evidence for speciation in Cannabis (Cannabaceae). Genet Resour Crop Evol 52:161\u2013180","journal-title":"Genet Resour Crop Evol"},{"issue":"20","key":"3_CR35","doi-asserted-by":"publisher","first-page":"587","DOI":"10.15585\/mmwr.mm6720a5","volume":"67","author":"RZ Horth","year":"2018","unstructured":"Horth RZ, Crouch B, Horowitz BZ et al (2018) Notes from the field: acute poisonings from a synthetic cannabinoid sold as cannabidiol - Utah, 2017-2018. MMWR Morb Mortal Wkly Rep 67(20):587\u2013588","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"3_CR36","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s13311-015-0373-7","volume":"12","author":"YL Hurd","year":"2015","unstructured":"Hurd YL, Yoon M, Manini AF et al (2015) Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics 12(4):807\u2013815","journal-title":"Neurotherapeutics"},{"key":"3_CR37","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1021\/cn5000524","volume":"5","author":"FA Iannotti","year":"2014","unstructured":"Iannotti FA, Hill CL, Leo A et al (2014) Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci 5:1131\u20131141","journal-title":"ACS Chem Neurosci"},{"issue":"10","key":"3_CR38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","volume":"30","author":"AA Izzo","year":"2009","unstructured":"Izzo AA, Borrelli F, Capasso R et al (2009) Nonpsychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30(10):515\u2013527","journal-title":"Trends Pharmacol Sci"},{"key":"3_CR39","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/0014-2999(74)90129-0","volume":"28","author":"IG Karniol","year":"1974","unstructured":"Karniol IG, Shirakawa I, Kasinski N et al (1974) Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 28:172\u2013177","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"3_CR40","first-page":"528","volume":"43","author":"MB Kaufman","year":"2018","unstructured":"Kaufman MB (2018) Pharmaceutical Approval Update. P T 43(9):528\u2013530","journal-title":"P T"},{"issue":"10","key":"3_CR41","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.21873\/anticanres.12924","volume":"38","author":"J Kenyon","year":"2018","unstructured":"Kenyon J, Liu W, Dalgleish A (2018) Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol. Anticancer Res 38(10):5831\u20135835","journal-title":"Anticancer Res"},{"key":"3_CR42","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2016.0034","volume":"2","author":"I Kerstin","year":"2017","unstructured":"Kerstin I, Grotenhermen F (2017) An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 2:139\u2013154","journal-title":"Cannabis Cannabinoid Res"},{"issue":"17","key":"3_CR43","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1212\/WNL.0000000000000363","volume":"82","author":"BS Koppel","year":"2014","unstructured":"Koppel BS, Brust JC, Fife T et al (2014) Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82(17):1556\u20131563","journal-title":"Neurology"},{"issue":"17","key":"3_CR44","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","volume":"78","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Brigo F, Trinka E et al (2018) Efficacy and safety of Cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs 78(17):1791\u20131804. https:\/\/doi.org\/10.1007\/s40265-018-0992-5","journal-title":"Drugs"},{"key":"3_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, Piomelli D, Pahlisch F et al (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94","journal-title":"Transl Psychiatry"},{"key":"3_CR46","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejim.2018.01.004","volume":"49","author":"CA MacCallum","year":"2018","unstructured":"MacCallum CA, Russo EB (2018) Practical considerations in medical cannabis administration and dosing. Eur J Intern Med 49:12\u201319","journal-title":"Eur J Intern Med"},{"issue":"32","key":"3_CR47","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.2174\/138161212802884780","volume":"18","author":"R Martin-Santos","year":"2012","unstructured":"Martin-Santos R, Crippa JA, Batalla A et al (2012) Acute effects of a single, oral dose of delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des 18(32):4966\u20134979","journal-title":"Curr Pharm Des"},{"issue":"9","key":"3_CR48","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/acn3.621","volume":"5","author":"B McCoy","year":"2018","unstructured":"McCoy B, Wang L, Zak M et al (2018) A prospective open-label trial of a CBD\/THC cannabis oil in dravet syndrome. Ann Clin Transl Neurol 5(9):1077\u20131088","journal-title":"Ann Clin Transl Neurol"},{"key":"3_CR49","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P, Robson P, Cubala WJ et al (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 175:225\u2013231","journal-title":"Am J Psychiatry"},{"key":"3_CR50","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2147\/JPR.S166617","volume":"11","author":"E Mondello","year":"2018","unstructured":"Mondello E, Quattrone D, Cardia L et al (2018) Cannabinoids and spinal cord stimulation for the treatment of failed back surgery syndrome refractory pain. J Pain Res 11:1761\u20131767","journal-title":"J Pain Res"},{"key":"3_CR51","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3389\/fphar.2017.00422","volume":"8","author":"P Morales","year":"2017","unstructured":"Morales P, Reggio PH, Jagerovic N (2017) An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol. Front Pharmacol 8:422","journal-title":"Front Pharmacol"},{"issue":"9","key":"3_CR52","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","volume":"38","author":"CJ Morgan","year":"2013","unstructured":"Morgan CJ, Das RK, Joye A et al (2013) Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 38(9):2433\u20132436","journal-title":"Addict Behav"},{"key":"3_CR53","first-page":"1","volume":"29","author":"CJ Morgan","year":"2011","unstructured":"Morgan CJ, Gardener C, Schafer G et al (2011) Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 29:1\u201310","journal-title":"Psychol Med"},{"issue":"4","key":"3_CR54","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1192\/bjp.bp.110.077503","volume":"197","author":"CJ Morgan","year":"2010","unstructured":"Morgan CJ, Schafer G, Freeman TP (2010) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 197(4):285\u2013290","journal-title":"Br J Psychiatry"},{"issue":"10","key":"3_CR55","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1017\/S0033291709005522","volume":"39","author":"PD Morrison","year":"2009","unstructured":"Morrison PD, Zois V, McKeown DA et al (2009) The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 39(10):1607\u20131616","journal-title":"Psychol Med"},{"key":"3_CR56","first-page":"130","volume":"4","author":"RJ Niesink","year":"2013","unstructured":"Niesink RJ, van Laar MW (2013) Does Cannabidiol Protect Against Adverse Psychological Effects of THC? Front Psych 4:130","journal-title":"Front Psych"},{"issue":"2","key":"3_CR57","doi-asserted-by":"publisher","first-page":"61","DOI":"10.14581\/jer.17012","volume":"7","author":"E Perucca","year":"2017","unstructured":"Perucca E (2017) Cannabinoids in the treatment of epilepsy: hard evidence at last? J Epilepsy Res 7(2):61\u201376","journal-title":"J Epilepsy Res"},{"issue":"2","key":"3_CR58","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1574889810666160517123938","volume":"10","author":"R Ranieri","year":"2016","unstructured":"Ranieri R, Marasco D, Bifulco M et al (2016) Phytocannabinoids and Cannabimimetic Drugs: recent patents in central nervous system disorders. Recent Pat CNS Drug Discov 10(2):157\u2013177","journal-title":"Recent Pat CNS Drug Discov"},{"issue":"1","key":"3_CR59","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13041-018-0395-2","volume":"11","author":"M Rodr\u00edguez-Mu\u00f1oz","year":"2018","unstructured":"Rodr\u00edguez-Mu\u00f1oz M, Onetti Y, Cort\u00e9s-Montero E et al (2018) Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor. Mol Brain 11(1):51","journal-title":"Mol Brain"},{"key":"3_CR77","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.nicl.2015.04.006","volume":"8","author":"K Romero","year":"2015","unstructured":"Romero K, Pavisian B, Staines WR, Anthony FA (2015) Multiple sclerosis, cannabis, and cognition: A structural MRI study. NeuroImage: Clinical 8:140\u2013147","journal-title":"NeuroImage: Clinical"},{"issue":"12","key":"3_CR60","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1001\/jama.2018.11914","volume":"320","author":"R Rubin","year":"2018","unstructured":"Rubin R (2018) The Path to the First FDA-Approved Cannabis-Derived Treatment and What Comes Next. JAMA 320(12):1227\u20131229","journal-title":"JAMA"},{"issue":"2","key":"3_CR61","doi-asserted-by":"publisher","first-page":"pyv092","DOI":"10.1093\/ijnp\/pyv092","volume":"19","author":"E Rzepa","year":"2016","unstructured":"Rzepa E, Tudge L, McCabe C (2016) The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers. Int J Neuropsychopharmacol 19(2):pyv092","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"3_CR62","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/09540261.2018.1460334","volume":"30","author":"KA Sagar","year":"2018","unstructured":"Sagar KA, Gruber SA (2018) Marijuana matters: reviewing the impact of marijuana on cognition, brain structure and function, & exploring policy implications and barriers to research. Int Rev Psychiatry 30(3):251\u2013267","journal-title":"Int Rev Psychiatry"},{"issue":"4","key":"3_CR63","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000493567","volume":"140","author":"N Sarid","year":"2018","unstructured":"Sarid N, Zada M, Lev-Ran S et al (2018) Medical cannabis use by hodgkin lymphoma patients: experience of a single center. Acta Haematol 140(4):194\u2013202","journal-title":"Acta Haematol"},{"key":"3_CR64","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.yebeh.2018.07.027","volume":"88","author":"KA Schoedel","year":"2018","unstructured":"Schoedel KA, Szeto I, Setnik B et al (2018) Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: a randomized, double-blind, controlled trial. Epilepsy Behav 88:162\u2013171","journal-title":"Epilepsy Behav"},{"issue":"8","key":"3_CR65","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40263-018-0550-4","volume":"32","author":"P Schonhofen","year":"2018","unstructured":"Schonhofen P, Bristot IJ, Crippa JA et al (2018) Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system. CNS Drugs 32(8):697\u2013712. https:\/\/doi.org\/10.1007\/s40263-018-0550-4","journal-title":"CNS Drugs"},{"issue":"6","key":"3_CR66","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/jamapsychiatry.2018.0335","volume":"75","author":"JC Scott","year":"2018","unstructured":"Scott JC, Slomiak ST, Jones JD et al (2018) Association of cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis.","journal-title":"JAMA Psychiat"},{"issue":"6","key":"3_CR78","first-page":"585","volume":"75","author":"P Seeman","year":"2016","unstructured":"Seeman P (2016) Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. JAMA Psychiatry 75(6):585\u2013595","journal-title":"JAMA Psychiatry"},{"key":"3_CR67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/can.2017.0043","volume":"3","author":"N Solowij","year":"2018","unstructured":"Solowij N, Broyd SJ, Beale C et al (2018) Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial. Cannabis Cannabinoid Res 3:21\u201334","journal-title":"Cannabis Cannabinoid Res"},{"issue":"11","key":"3_CR68","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","volume":"32","author":"L Taylor","year":"2018","unstructured":"Taylor L, Gidal B, Blakey G et al (2018) A Phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs 32(11):1053\u20131067","journal-title":"CNS Drugs"},{"issue":"24","key":"3_CR69","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1001\/jama.2015.6613","volume":"313","author":"R Vandrey","year":"2015","unstructured":"Vandrey R, Raber JC, Raber ME et al (2015) Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products. JAMA 313(24):2491\u20132493","journal-title":"JAMA"},{"issue":"3","key":"3_CR70","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1001\/jamapsychiatry.2015.3278","volume":"73","author":"ND Volkow","year":"2016","unstructured":"Volkow ND, Swanson JM, Evins AE et al (2016) Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiat 73(3):292\u2013297","journal-title":"JAMA Psychiat"},{"issue":"42","key":"3_CR71","doi-asserted-by":"publisher","first-page":"6366","DOI":"10.2174\/1381612822666160822151323","volume":"22","author":"A Weinstein","year":"2016","unstructured":"Weinstein A, Livny A, Weizman A (2016) Brain imaging studies on the cognitive, pharmacological and neurobiological effects of cannabis in humans: evidence from studies of adult users. Curr Pharm Des 22(42):6366\u20136379","journal-title":"Curr Pharm Des"},{"issue":"24","key":"3_CR72","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","volume":"313","author":"PF Whiting","year":"2015","unstructured":"Whiting PF, Wolff RF, Deshpande S (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313(24):2456\u20132473","journal-title":"JAMA"},{"issue":"3","key":"3_CR73","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1177\/0269881117744995","volume":"32","author":"JA Yanes","year":"2018","unstructured":"Yanes JA, Riedel MC, Ray KL et al (2018) Neuroimaging meta-analysis of cannabis use studies reveals convergent functional alterations in brain regions supporting cognitive control and reward processing. J Psychopharmacol 32(3):283\u2013295","journal-title":"J Psychopharmacol"},{"key":"3_CR74","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21767\/2471-982X.100016","volume":"3","author":"M Yassin","year":"2017","unstructured":"Yassin M, Robinson D (2017) Effect of Adding Medical Cannabis Treatment (MCT) to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single center study. Int J Anesth Pain Med 3:2","journal-title":"Int J Anesth Pain Med"},{"key":"3_CR75","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/0269881108096519","volume":"23","author":"AW Zuardi","year":"2009","unstructured":"Zuardi AW, Crippa JA, Hallak JE et al (2009) Cannabidiol for the treatment of psychosis in Parkinson\u2019s disease. J Psychopharmacol 23:979\u2013983","journal-title":"J Psychopharmacol"},{"issue":"3","key":"3_CR76","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF00432554","volume":"76","author":"AW Zuardi","year":"1982","unstructured":"Zuardi AW, Shirakawa I, Finkelfarb E et al (1982) Action of cannabidiol on the anxiety and other effects produced by delta9-THC in normal subjects. Psychopharmacology 76(3):245\u2013250","journal-title":"Psychopharmacology"}],"container-title":["Advances in Experimental Medicine and Biology","Cannabinoids and Neuropsychiatric Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-57369-0_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T10:31:27Z","timestamp":1608201087000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-57369-0_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"ISBN":["9783030573683","9783030573690"],"references-count":78,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-57369-0_3","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]},"assertion":[{"value":"18 December 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}